Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Accumulated Expenses: 2020-2023

Historic Other Accumulated Expenses for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $48,000.

  • Candel Therapeutics' Other Accumulated Expenses rose 54.84% to $48,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $48,000, marking a year-over-year increase of 54.84%. This contributed to the annual value of $48,000 for FY2022, which is 85.63% down from last year.
  • Per Candel Therapeutics' latest filing, its Other Accumulated Expenses stood at $48,000 for Q3 2023, which was down 0.00% from $48,000 recorded in Q2 2023.
  • Candel Therapeutics' 5-year Other Accumulated Expenses high stood at $334,000 for Q4 2021, and its period low was $31,000 during Q3 2022.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $55,500 (2022), whereas its average is $116,700.
  • As far as peak fluctuations go, Candel Therapeutics' Other Accumulated Expenses skyrocketed by 78.61% in 2021, and later tumbled by 86.46% in 2022.
  • Candel Therapeutics' Other Accumulated Expenses (Quarterly) stood at $187,000 in 2020, then soared by 78.61% to $334,000 in 2021, then crashed by 85.63% to $48,000 in 2022, then soared by 54.84% to $48,000 in 2023.
  • Its Other Accumulated Expenses was $48,000 in Q3 2023, compared to $48,000 in Q2 2023 and $48,000 in Q1 2023.